DSM Supporting AREDS Study

PARSIPPANY, N.J.—DSM Nutritional Products announced it is supporting the recently announced nationwide Age-Related Eye Disease Study 2 (AREDS2)—coordinated through the National Eye Institute—by providing the lutein, zeaxanthin and omega-3 fatty acid dietary supplements to use in the trial. AREDS2 is designed to refine the findings of the original AREDS study, which found high-dose antioxidant vitamins and minerals could reduce the progression of age-related macular degeneration (AMD). The AREDS2 formulation will include vitamins C and E, beta-carotene, zinc and copper, plus 10 mg of lutein and 2 mg of zeaxanthin, as well as fish oil-based omega-3s.

“This study is very exciting and we believe it may help provide further support on the health benefits of lutein, zeaxanthin and omega-3 fatty acid supplementation and demonstrate their potential to help save the sight of thousands of individuals every year,” said James Elliott, Ph.D., director of nutritional science for DSM (www.nutraaccess.com).